Structural basis of antagonist selectivity in endothelin receptors.
Journal
Cell discovery
ISSN: 2056-5968
Titre abrégé: Cell Discov
Pays: England
ID NLM: 101661034
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
26
02
2024
accepted:
30
06
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
epublish
Résumé
Endothelins and their receptors, ET
Identifiants
pubmed: 39075075
doi: 10.1038/s41421-024-00705-9
pii: 10.1038/s41421-024-00705-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
79Informations de copyright
© 2024. The Author(s).
Références
Dhaun, N. & Webb, D. J. Endothelins in cardiovascular biology and therapeutics. Nat. Rev. Cardiol. 16, 491–502 (2019).
pubmed: 30867577
doi: 10.1038/s41569-019-0176-3
Barton, M. & Yanagisawa, M. Endothelin: 30 years from discovery to therapy. Hypertension 74, 1232–1265 (2019).
pubmed: 31679425
doi: 10.1161/HYPERTENSIONAHA.119.12105
Davenport, A. P. et al. Endothelin. Pharmacol. Rev. 68, 357–418 (2016).
pubmed: 26956245
pmcid: 4815360
doi: 10.1124/pr.115.011833
Houde, M., Desbiens, L. & D’Orleans-Juste, P. Endothelin-1: Biosynthesis, signaling and vasoreactivity. Adv. Pharmacol. 77, 143–175 (2016).
pubmed: 27451097
doi: 10.1016/bs.apha.2016.05.002
Shihoya, W. et al. Crystal structures of human ETB receptor provide mechanistic insight into receptor activation and partial activation. Nat. Commun. 9, 4711 (2018).
pubmed: 30413709
pmcid: 6226434
doi: 10.1038/s41467-018-07094-0
Haryono, A., Ramadhiani, R., Ryanto, G. R. T. & Emoto, N. Endothelin and the cardiovascular system: the long journey and where we are going. Biology 11, 759 (2022).
pubmed: 35625487
pmcid: 9138590
doi: 10.3390/biology11050759
Rodriguez-Pascual, F., Busnadiego, O., Lagares, D. & Lamas, S. Role of endothelin in the cardiovascular system. Pharmacol. Res. 63, 463–472 (2011).
pubmed: 21296157
doi: 10.1016/j.phrs.2011.01.014
Hassoun, P. M. Pulmonary arterial hypertension. N. Engl. J. Med. 385, 2361–2376 (2021).
pubmed: 34910865
doi: 10.1056/NEJMra2000348
Liu, C., Chen, J., Gao, Y., Deng, B. & Liu, K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst. Rev. 3, CD004434 (2021).
pubmed: 33765691
Nunes, J. P. L. et al. Prevalence of auto-antibodies associated to pulmonary arterial hypertension in scleroderma - A review. Autoimmun. Rev. 17, 1186–1201 (2018).
pubmed: 30316987
doi: 10.1016/j.autrev.2018.06.009
Bolli, M. H. et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. J. Med. Chem. 55, 7849–7861 (2012).
pubmed: 22862294
doi: 10.1021/jm3009103
Patel, T. & McKeage, K. Macitentan: first global approval. Drugs 74, 127–133 (2014).
pubmed: 24297706
doi: 10.1007/s40265-013-0156-6
Croxtall, J. D. & Keam, S. J. Ambrisentan. Drugs 68, 2195–2204 (2008).
pubmed: 18840007
doi: 10.2165/00003495-200868150-00008
Galie, N. et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010–3019 (2008).
pubmed: 18506008
doi: 10.1161/CIRCULATIONAHA.107.742510
Newman, J. H., Kar, S. & Kirkpatrick, P. Ambrisentan. Nat. Rev. Drug Discov. 6, 697–698 (2007).
pubmed: 17907344
doi: 10.1038/nrd2402
Martinez-Diaz, I. et al. Endothelin receptor antagonists in kidney disease. Int. J. Mol. Sci. 24, 3427 (2023).
pubmed: 36834836
pmcid: 9965540
doi: 10.3390/ijms24043427
Stern, E. P. et al. Zibotentan in systemic sclerosis-associated chronic kidney disease: a phase II randomised placebo-controlled trial. Arthritis Res. Ther. 24, 130 (2022).
pubmed: 35650639
pmcid: 9158153
doi: 10.1186/s13075-022-02818-6
Schlaich, M. P. et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet 400, 1927–1937 (2022).
pubmed: 36356632
doi: 10.1016/S0140-6736(22)02034-7
Trachtman, H. et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J. Am. Soc. Nephrol. 29, 2745–2754 (2018).
pubmed: 30361325
pmcid: 6218860
doi: 10.1681/ASN.2018010091
Koyama, Y. Endothelin ET(B) receptor-mediated astrocytic activation: pathological roles in brain disorders. Int. J. Mol. Sci. 22, 4333 (2021).
pubmed: 33919338
pmcid: 8122402
doi: 10.3390/ijms22094333
Vatter, H. et al. Characterization of the endothelin-B receptor expression and vasomotor function during experimental cerebral vasospasm. Neurosurgery 60, 1100–1108 (2007).
pubmed: 17538385
doi: 10.1227/01.NEU.0000255471.75752.4B
Shah, P. K. Active and passive vaccination for pulmonary arterial hypertension: a novel therapeutic paradigm. J. Am. Coll. Cardiol. 73, 2581–2583 (2019).
pubmed: 31118152
doi: 10.1016/j.jacc.2019.02.064
Zhang, C. et al. Therapeutic monoclonal antibody antagonizing endothelin receptor A for pulmonary arterial hypertension. J. Pharmacol. Exp. Ther. 370, 54–61 (2019).
pubmed: 30992315
doi: 10.1124/jpet.118.252700
Dai, Y. et al. Immunotherapy of endothelin-1 receptor type A for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 73, 2567–2580 (2019).
pubmed: 31118151
doi: 10.1016/j.jacc.2019.02.067
Shihoya, W. et al. Activation mechanism of endothelin ETB receptor by endothelin-1. Nature 537, 363–368 (2016).
pubmed: 27595334
doi: 10.1038/nature19319
Shihoya, W. et al. X-ray structures of endothelin ETB receptor bound to clinical antagonist bosentan and its analog. Nat. Struct. Mol. Biol. 24, 758–764 (2017).
pubmed: 28805809
doi: 10.1038/nsmb.3450
Nagiri, C. et al. Crystal structure of human endothelin ET(B) receptor in complex with peptide inverse agonist IRL2500. Commun. Biol. 2, 236 (2019).
pubmed: 31263780
pmcid: 6588608
doi: 10.1038/s42003-019-0482-7
Izume, T., Miyauchi, H., Shihoya, W. & Nureki, O. Crystal structure of human endothelin ET(B) receptor in complex with sarafotoxin S6b. Biochem. Biophys. Res. Commun. 528, 383–388 (2020).
pubmed: 32001000
doi: 10.1016/j.bbrc.2019.12.091
Sano, F. K., Akasaka, H., Shihoya, W. & Nureki, O. Cryo-EM structure of the endothelin-1-ET(B)-G(i) complex. Elife 12, e85821 (2023).
pubmed: 37096326
pmcid: 10129325
doi: 10.7554/eLife.85821
Ji, Y. et al. Structural basis of peptide recognition and activation of endothelin receptors. Nat. Commun. 14, 1268 (2023).
pubmed: 36882417
pmcid: 9992518
doi: 10.1038/s41467-023-36998-9
Dai, Y. et al. Long-term effect of a vaccine targeting endothelin-1 receptor type A in pulmonary arterial hypertension. Front. Cardiovasc. Med. 8, 683436 (2021).
pubmed: 34222378
pmcid: 8247646
doi: 10.3389/fcvm.2021.683436
Chun, E. et al. Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20, 967–976 (2012).
pubmed: 22681902
pmcid: 3375611
doi: 10.1016/j.str.2012.04.010
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).
pubmed: 34265844
pmcid: 8371605
doi: 10.1038/s41586-021-03819-2
Mukherjee, S. et al. Synthetic antibodies against BRIL as universal fiducial marks for single-particle cryoEM structure determination of membrane proteins. Nat. Commun. 11, 1598 (2020).
pubmed: 32221310
pmcid: 7101349
doi: 10.1038/s41467-020-15363-0
Ereno-Orbea, J. et al. Structural basis of enhanced crystallizability induced by a molecular chaperone for antibody antigen-binding fragments. J. Mol. Biol. 430, 322–336 (2018).
pubmed: 29277294
doi: 10.1016/j.jmb.2017.12.010
Iglarz, M. et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736–745 (2008).
pubmed: 18780830
doi: 10.1124/jpet.108.142976
Boss, C., Bolli, M. H. & Gatfield, J. From bosentan (Tracleer(R)) to macitentan (Opsumit(R)): the medicinal chemistry perspective. Bioorg. Med. Chem. Lett. 26, 3381–3394 (2016).
pubmed: 27321813
doi: 10.1016/j.bmcl.2016.06.014
Ihara, M. et al. A novel radioligand [125I]BQ-3020 selective for endothelin (ETB) receptors. Life Sci. 51, PL47–PL52 (1992).
pubmed: 1321937
doi: 10.1016/0024-3205(92)90418-O
Zhou, Q. et al. Common activation mechanism of class A GPCRs. Elife 8, e50279 (2019).
pubmed: 31855179
pmcid: 6954041
doi: 10.7554/eLife.50279
Evans, R. et al. Protein complex prediction with AlphaFold-Multimer. bioRxiv https://doi.org/10.1101/2021.10.04.463034 (2022).
Tsutsumi, N. et al. Structure of human Frizzled5 by fiducial-assisted cryo-EM supports a heterodimeric mechanism of canonical Wnt signaling. Elife 9, e58464 (2020).
pubmed: 32762848
pmcid: 7442489
doi: 10.7554/eLife.58464
Zhou, Y. et al. Molecular insights into ligand recognition and G protein coupling of the neuromodulatory orphan receptor GPR139. Cell Res. 32, 210–213 (2022).
pubmed: 34916631
doi: 10.1038/s41422-021-00591-w
Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017).
pubmed: 28250466
pmcid: 5494038
doi: 10.1038/nmeth.4193
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 (2017).
pubmed: 28165473
doi: 10.1038/nmeth.4169
Bepler, T. et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat. Methods 16, 1153–1160 (2019).
pubmed: 31591578
pmcid: 6858545
doi: 10.1038/s41592-019-0575-8
Chen, H., Huang, W. & Li, X. Structures of oxysterol sensor EBI2/GPR183, a key regulator of the immune response. Structure 30, 1016–1024.e5 (2022).
pubmed: 35537452
pmcid: 9271633
doi: 10.1016/j.str.2022.04.006
Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 (2004).
pubmed: 15264254
doi: 10.1002/jcc.20084
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010).
pubmed: 20383002
pmcid: 2852313
doi: 10.1107/S0907444910007493
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 75, 861–877 (2019).
pubmed: 31588918
pmcid: 6778852
doi: 10.1107/S2059798319011471
Williams, C. J. et al. MolProbity: more and better reference data for improved all-atom structure validation. Protein Sci. 27, 293–315 (2018).
pubmed: 29067766
doi: 10.1002/pro.3330
Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82 (2021).
pubmed: 32881101
doi: 10.1002/pro.3943
Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71–73 (2017).
pubmed: 27819658
doi: 10.1038/nmeth.4067
Vanommeslaeghe, K. et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671–690 (2010).
pubmed: 19575467
pmcid: 2888302
doi: 10.1002/jcc.21367
Wu, E. L. et al. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. J. Comput. Chem. 35, 1997–2004 (2014).
pubmed: 25130509
pmcid: 4165794
doi: 10.1002/jcc.23702
Darden, T., York, D. & Pedersen, L. Particle mesh ewald - an N.log(N) method for Ewald sums in large systems. J. Chem. Phys. 98, 10089–10092 (1993).
doi: 10.1063/1.464397
Humphrey, W., Dalke, A. & Schulten, K. VMD: visual molecular dynamics. J. Mol. Graph. 14, 33–38 (1996).
pubmed: 8744570
doi: 10.1016/0263-7855(96)00018-5